Viking Therapeutics (VKTX) to Release Earnings on Wednesday

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) is expected to be releasing its earnings data before the market opens on Wednesday, April 23rd. Analysts expect Viking Therapeutics to post earnings of ($0.34) per share for the quarter. Individual that are interested in participating in the company's earnings conference call can do so using this link.

Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings results on Wednesday, February 5th. The biotechnology company reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.27) by ($0.05). During the same quarter last year, the business posted ($0.25) EPS. On average, analysts expect Viking Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Viking Therapeutics Price Performance

Viking Therapeutics stock traded up $0.34 during midday trading on Friday, hitting $23.94. The company's stock had a trading volume of 5,025,769 shares, compared to its average volume of 4,042,513. The company has a 50-day moving average price of $26.94 and a two-hundred day moving average price of $41.85. Viking Therapeutics has a 1-year low of $18.92 and a 1-year high of $81.86. The company has a market cap of $2.69 billion, a price-to-earnings ratio of -23.94 and a beta of 0.84.

Insider Buying and Selling

In related news, Director Sarah Kathryn Rouan bought 1,240 shares of the business's stock in a transaction on Monday, March 31st. The shares were purchased at an average cost of $24.15 per share, with a total value of $29,946.00. Following the acquisition, the director now owns 1,240 shares of the company's stock, valued at $29,946. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.70% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. The Goldman Sachs Group initiated coverage on Viking Therapeutics in a research report on Tuesday, April 8th. They set a "neutral" rating and a $30.00 price target on the stock. B. Riley reiterated a "buy" rating and set a $96.00 price objective (down from $109.00) on shares of Viking Therapeutics in a research note on Friday, February 7th. Raymond James boosted their target price on shares of Viking Therapeutics from $122.00 to $125.00 and gave the company a "strong-buy" rating in a research report on Thursday, February 6th. Scotiabank initiated coverage on shares of Viking Therapeutics in a research note on Thursday, February 13th. They issued a "sector outperform" rating and a $102.00 price objective on the stock. Finally, Piper Sandler reduced their target price on Viking Therapeutics from $74.00 to $71.00 and set an "overweight" rating on the stock in a report on Thursday, February 6th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $89.75.

Viking Therapeutics Company Profile

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.